Are you over 18 and want to see adult content?
More Annotations
A complete backup of orcasislandchefservices.com
Are you over 18 and want to see adult content?
A complete backup of newgeography.com
Are you over 18 and want to see adult content?
A complete backup of laboiteapandore.fr
Are you over 18 and want to see adult content?
A complete backup of moneyadviceandhelp.com
Are you over 18 and want to see adult content?
A complete backup of fossils-facts-and-finds.com
Are you over 18 and want to see adult content?
Favourite Annotations
Ιερά Μονή Παντοκράτορος Μελισσοχωρίου
Are you over 18 and want to see adult content?
Megashare - Watch Megashare Movies Online
Are you over 18 and want to see adult content?
Metal Florence serramenti porte infissi - Metal Florence serramenti porte infissi
Are you over 18 and want to see adult content?
Feng Shui Blog To Attract Good Luck - Feng Shui Beginner
Are you over 18 and want to see adult content?
Men's jewellery and men's accessories - Free delivery over $150 - Trendhim.co.nz
Are you over 18 and want to see adult content?
Root of Good - Retired in 2013 at age 33. Life is Good.
Are you over 18 and want to see adult content?
Text
more.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
NRAS Q61K - MY CANCER GENOME Biomarker-Directed Therapies. NRAS Q61K is a predictive biomarker for use of binimetinib, cetuximab, and panitumumab in patients. Of the therapies with NRAS Q61K as a predictive biomarker, 2 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting. POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer,and
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved and 7 have NCCN guidelines in at least one clinical setting. IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .ARID1A MUTATION
ARID1A Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Uveal Melanoma +.RAD51C MUTATION
RAD51C Mutation is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51C Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) . LRP1B - MY CANCER GENOME LRP1B is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) . Diffuse Glioma +. LRP1B is altered in 3.04% of diffuse glioma patients .ERBB2 L755_E757DEL
ERBB2 is altered in 13.78% of breast carcinoma patients with ERBB2 L755_E757del present in 0.01% of all breast carcinoma patients . ERBB2 L755_E757del is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 L755_E757del and breast carcinoma as inclusion HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
NRAS Q61K - MY CANCER GENOME Biomarker-Directed Therapies. NRAS Q61K is a predictive biomarker for use of binimetinib, cetuximab, and panitumumab in patients. Of the therapies with NRAS Q61K as a predictive biomarker, 2 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting. POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer,and
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved and 7 have NCCN guidelines in at least one clinical setting. IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .ARID1A MUTATION
ARID1A Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Uveal Melanoma +.RAD51C MUTATION
RAD51C Mutation is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51C Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) . LRP1B - MY CANCER GENOME LRP1B is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) . Diffuse Glioma +. LRP1B is altered in 3.04% of diffuse glioma patients .ERBB2 L755_E757DEL
ERBB2 is altered in 13.78% of breast carcinoma patients with ERBB2 L755_E757del present in 0.01% of all breast carcinoma patients . ERBB2 L755_E757del is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 L755_E757del and breast carcinoma as inclusion AZD5305 - MY CANCER GENOME An orally bioavailable inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, PARP inhibitor AZD5305 selectively targets and binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. RIT1 - MY CANCER GENOME Ras-like without CAAX 1 (RIT1) is a gene that encodes a protein that belongs to the Ras-related GTPases subfamily. The protein regulates p38 MAPK-dependent signaling cascades that are related to cellular stress. Missense mutations, nonsense mutations, silent mutations, and in-frame deletions are observed in cancers such as intestinal cancer IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) . CHEK1 - MY CANCER GENOME CHEK1 is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain CHEK1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) . High Grade Ovarian Serous Adenocarcinoma +.NBN MUTATION
NBN Mutation is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) . Pancreatic Carcinoma +.CCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients . MAP2K4 - MY CANCER GENOME MAP2K4 is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) . Squamous Cell Lung Carcinoma +.PALB2 MUTATION
PALB2 Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Non-Hodgkin Lymphoma +. CDKN2A - MY CANCER GENOME CDKN2A is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) . Appendix Carcinoma +. CDKN2A is altered in 0.66% of appendix carcinoma patients . WWW.MYCANCERGENOME.ORG www.mycancergenome.org HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS Clinical Implications of Molecular Biomarkers. My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair.PIK3CA E545K
PIK3CA E545K is present in 2.61% of AACR GENIE cases, with breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, bladder urothelial carcinoma, and breast invasive lobular carcinoma having the greatest prevalence . KRAS G12A - MY CANCER GENOME KRAS G12A is present in 0.75% of AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, colorectal adenocarcinoma, endometrial endometrioid adenocarcinoma, and rectal adenocarcinoma having the greatest prevalence . MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. LRP1B - MY CANCER GENOME Low density lipoprotein receptor-related protein 1B (LRP1B) is a gene that encodes a protein that is a member of the low density lipoprotein (LDL) receptor family.BERZOSERTIB
Berzosertib has been investigated in 20 clinical trials, of which 18 are open and 2 are closed. Of the trials investigating berzosertib, 8 are phase 1 (6 open), 4 are phase 1/phase 2 (4CCND1 MUTATION
CCND1 Mutation is present in 0.62% of AACR GENIE cases, with endometrial endometrioid adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, endometrial carcinoma, and mantle cell lymphoma having the greatest prevalence .ARID1A MUTATION
ARID1A Mutation is present in 5.58% of AACR GENIE cases, with lung adenocarcinoma, endometrial endometrioid adenocarcinoma, bladder urothelial carcinoma, colon adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence . NRAS Q61K - MY CANCER GENOME NRAS Q61K is present in 0.59% of AACR GENIE cases, with melanoma, cutaneous melanoma, colon adenocarcinoma, colorectal adenocarcinoma, and melanoma of unknown primary having the HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS Clinical Implications of Molecular Biomarkers. My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair.PIK3CA E545K
PIK3CA E545K is present in 2.61% of AACR GENIE cases, with breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, bladder urothelial carcinoma, and breast invasive lobular carcinoma having the greatest prevalence . KRAS G12A - MY CANCER GENOME KRAS G12A is present in 0.75% of AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, colorectal adenocarcinoma, endometrial endometrioid adenocarcinoma, and rectal adenocarcinoma having the greatest prevalence . MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. LRP1B - MY CANCER GENOME Low density lipoprotein receptor-related protein 1B (LRP1B) is a gene that encodes a protein that is a member of the low density lipoprotein (LDL) receptor family.BERZOSERTIB
Berzosertib has been investigated in 20 clinical trials, of which 18 are open and 2 are closed. Of the trials investigating berzosertib, 8 are phase 1 (6 open), 4 are phase 1/phase 2 (4CCND1 MUTATION
CCND1 Mutation is present in 0.62% of AACR GENIE cases, with endometrial endometrioid adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, endometrial carcinoma, and mantle cell lymphoma having the greatest prevalence .ARID1A MUTATION
ARID1A Mutation is present in 5.58% of AACR GENIE cases, with lung adenocarcinoma, endometrial endometrioid adenocarcinoma, bladder urothelial carcinoma, colon adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence . NRAS Q61K - MY CANCER GENOME NRAS Q61K is present in 0.59% of AACR GENIE cases, with melanoma, cutaneous melanoma, colon adenocarcinoma, colorectal adenocarcinoma, and melanoma of unknown primary having the RIT1 - MY CANCER GENOME Ras-like without CAAX 1 (RIT1) is a gene that encodes a protein that belongs to the Ras-related GTPases subfamily. The protein regulates p38 MAPK-dependent signaling cascades that are related to EGFR L858R - MY CANCER GENOME EGFR L858R is present in 1.12% of AACR GENIE cases, with lung adenocarcinoma, non-small cell lung carcinoma, small cell lung carcinoma, squamous cell lungNBN MUTATION
NBN Mutation is present in 1.16% of AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and bladder urothelial carcinoma having the greatest prevalence . AZD5305 - MY CANCER GENOME Azd5305 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating azd5305, 1 is phase 1 (1open).
ERBB2 S310F
ERBB2 S310F is present in 0.31% of AACR GENIE cases, with bladder urothelial carcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, rectal adenocarcinoma, and colon adenocarcinoma having the greatest prevalence . IDH1 R132C - MY CANCER GENOME IDH1 R132C is present in 0.62% of AACR GENIE cases, with intrahepatic cholangiocarcinoma, acute myeloid leukemia, cutaneous melanoma, melanoma, and cholangiocarcinoma having the CDKN2A - MY CANCER GENOME The Cyclin-dependent kinase inhibitor 2A (CDKN2A) gene encodes several protein isoforms that function as inhibitors of CDK4 and ARF. Missense mutations, nonsense mutations, silent mutations, in-frame deletions, frameshift deletions and insertions, and whole gene deletions are observed in cancer such as cancers of the genital tract, mesothelioma, ovarian cancer, skin cancer, and multiple otherPALB2 MUTATION
PALB2 Mutation is present in 1.52% of AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence . EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is present in 1.28% of AACR GENIE cases, with lung adenocarcinoma, non-small cell lung carcinoma, small cell lung carcinoma, colon adenocarcinoma, and squamous cell lung carcinoma having the greatest prevalence .JNJ-74856665
Jnj-74856665 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating jnj-74856665, 1 isphase 1 (1 open).
HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS G12C - MY CANCER GENOME NRAS G12C is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS G12C and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) . Pancreatic DuctalAdenocarcinoma +.
IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .MYC OVEREXPRESSION
MYC Overexpression is an inclusion criterion in 2 clinical trials for double-hit lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Overexpression and double-hit lymphoma as inclusion criteria, 2 are phase 1 (0 open) . MYC is altered in 1.9% of multiple myeloma patients . KRAS A146T - MY CANCER GENOME Biomarker-Directed Therapies. KRAS A146T is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS A146T as a predictive biomarker, 2 are FDA-approved and 7ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS G12C - MY CANCER GENOME NRAS G12C is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS G12C and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) . Pancreatic DuctalAdenocarcinoma +.
IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .MYC OVEREXPRESSION
MYC Overexpression is an inclusion criterion in 2 clinical trials for double-hit lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Overexpression and double-hit lymphoma as inclusion criteria, 2 are phase 1 (0 open) . MYC is altered in 1.9% of multiple myeloma patients . KRAS A146T - MY CANCER GENOME Biomarker-Directed Therapies. KRAS A146T is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS A146T as a predictive biomarker, 2 are FDA-approved and 7ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved andJNJ-74856665
Jnj-74856665 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating jnj-74856665, 1 is phase 1 (1 open). Complex karyotype, Monosomy 7, and NPM1-MLF1 Fusion are the most frequent biomarker inclusion criteria for jnj-74856665 clinical trials. Myelodysplastic syndromes is the most common diseaseCCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients . EGFR L858R - MY CANCER GENOME EGFR L858R is a predictive biomarker for use of afatinib, erlotinib, gefitinib, osimertinib, capmatinib, crizotinib, dacomitinib, cetuximab, and pembrolizumab in patients. Of the therapies with EGFR L858R as a predictive biomarker, 6 are FDA-approved and 8 have NCCN guidelines in at least one clinical setting.BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),CDKN2A D108Y
CDKN2A D108Y is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A D108Y and glioblastoma as inclusion criteria, 2 are phase 2 (1 open) . Head And Neck Squamous Cell Carcinoma +. CDKN2A is altered in 23.69% of head and neck squamous cell carcinomapatients
KIT W557R - MY CANCER GENOME KIT W557R is a predictive biomarker for use of imatinib, dasatinib, nilotinib, sorafenib, and sunitinib in patients. Thymic carcinoma and melanoma have the most therapies targeted against KIT W557R or its related pathways . Dasatinib +. Thymic Carcinoma -. CLINICAL TRIAL: NCT04042480 NCT04042480. Description: This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. LRP1B - MY CANCER GENOME LRP1B is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) . Diffuse Glioma +. LRP1B is altered in 3.04% of diffuse glioma patients . HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS G12C - MY CANCER GENOME NRAS G12C is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS G12C and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) . Pancreatic DuctalAdenocarcinoma +.
IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .MYC OVEREXPRESSION
MYC Overexpression is an inclusion criterion in 2 clinical trials for double-hit lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Overexpression and double-hit lymphoma as inclusion criteria, 2 are phase 1 (0 open) . MYC is altered in 1.9% of multiple myeloma patients . KRAS A146T - MY CANCER GENOME Biomarker-Directed Therapies. KRAS A146T is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS A146T as a predictive biomarker, 2 are FDA-approved and 7ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS G12C - MY CANCER GENOME NRAS G12C is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS G12C and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) . Pancreatic DuctalAdenocarcinoma +.
IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .MYC OVEREXPRESSION
MYC Overexpression is an inclusion criterion in 2 clinical trials for double-hit lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Overexpression and double-hit lymphoma as inclusion criteria, 2 are phase 1 (0 open) . MYC is altered in 1.9% of multiple myeloma patients . KRAS A146T - MY CANCER GENOME Biomarker-Directed Therapies. KRAS A146T is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS A146T as a predictive biomarker, 2 are FDA-approved and 7ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved andJNJ-74856665
Jnj-74856665 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating jnj-74856665, 1 is phase 1 (1 open). Complex karyotype, Monosomy 7, and NPM1-MLF1 Fusion are the most frequent biomarker inclusion criteria for jnj-74856665 clinical trials. Myelodysplastic syndromes is the most common diseaseCCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients . EGFR L858R - MY CANCER GENOME EGFR L858R is a predictive biomarker for use of afatinib, erlotinib, gefitinib, osimertinib, capmatinib, crizotinib, dacomitinib, cetuximab, and pembrolizumab in patients. Of the therapies with EGFR L858R as a predictive biomarker, 6 are FDA-approved and 8 have NCCN guidelines in at least one clinical setting.BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),CDKN2A D108Y
CDKN2A D108Y is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A D108Y and glioblastoma as inclusion criteria, 2 are phase 2 (1 open) . Head And Neck Squamous Cell Carcinoma +. CDKN2A is altered in 23.69% of head and neck squamous cell carcinomapatients
KIT W557R - MY CANCER GENOME KIT W557R is a predictive biomarker for use of imatinib, dasatinib, nilotinib, sorafenib, and sunitinib in patients. Thymic carcinoma and melanoma have the most therapies targeted against KIT W557R or its related pathways . Dasatinib +. Thymic Carcinoma -. CLINICAL TRIAL: NCT04042480 NCT04042480. Description: This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. LRP1B - MY CANCER GENOME LRP1B is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) . Diffuse Glioma +. LRP1B is altered in 3.04% of diffuse glioma patients .CLINICAL TRIALS
DISEASES
BIOMARKERS
DRUGS
PATHWAYS
CLINICAL IMPLICATIONS OF MOLECULAR BIOMARKERS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
Learn About My Cancer Genome MOLECULAR MEDICINE RESOURCESTARGETED THERAPIES
Types, classification, and naming; FDA approved therapiesLearn More
MOLECULAR TESTING
Biomarkers can be detected using multiple types of testsLearn More
MOLECULAR TUMOR BOARD Molecular tumor board for patients with somatic or germline mutationsLearn More
GLOSSARY
Understand terms related to precision medicineLearn More
ABOUT
Home
What Is My Cancer Genome? My Cancer Genome Data Sources Legal Policies & Licensing Letter from the EditorsAcknowledgments
About GenomOncology
Contributors
How to Give to My Cancer GenomeMOLECULAR MEDICINE
Types of Molecular Tumor TestingCirculating DNA
Detecting Gene Alterations in CancersGlossary
Targeted Therapies
Molecular Tumor BoardCONTENT TYPES
Clinical Trials
Diseases
Biomarkers
Drugs
Pathways
My Cancer Genome is managed by the Vanderbilt-Ingram Cancer Center Copyright © 2010 - 2017 MY CANCER GENOMEDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0